A Machine Learning Model to Predict Immunotherapy Response in Cancer Patients

Immunotherapy is a new cancer treatment that activates the body's immune system to fight against cancer cells without using chemotherapy or radiotherapy. It has fewer side effects than conventional anticancer drugs because it attacks only cancer cells using the body's immune system. In addition, because it uses the memory and adaptability of the immune system, patients who have benefited from its therapeutic effects experience sustained anticancer effects.

The recently developed immune checkpoint inhibitor has considerably improved the survival rate of patients with cancer. However, the problem with cancer immunotherapy is that only approximately 30% of cancer patients receive benefits from its therapeutic effect, and the current diagnostic techniques do not accurately predict the patient's response to the treatment.

Under this circumstance, the research team led by Professor Sanguk Kim (Department of Life Sciences) at POSTECH is gaining attention as they have improved the accuracy of predicting patient response to immune checkpoint inhibitors (ICIs) by using network-based machine learning. The research team discovered new network-based biomarkers by analyzing the clinical results of more than 700 patients with three different cancers (melanoma, gastric cancer, and bladder cancer) and the transcriptome data of the patients' cancer tissues. By utilizing the network-based biomarkers, the team successfully developed artificial intelligence that could predict the response to anticancer treatment. The team further proved that the treatment response prediction based on the newly discovered biomarkers was superior to that based on conventional anticancer treatment biomarkers including immunotherapy targets and tumor microenvironment markers.

In their previous study, the research team had developed machine learning that could predict drug responses to chemotherapy in patients with gastric or bladder cancer. This study has shown that artificial intelligence using the interactions between genes in a biological network could successfully predict the patient response to not only chemotherapy, but also immunotherapy in multiple cancer types.

This study helps detect patients who will respond to immunotherapy in advance and establish treatment plans, resulting in customized precision medicine with more patients to benefit from cancer treatments. Supported by the POSTECH Medical Device Innovation Center, the Graduate School of Artificial Intelligence, and ImmunoBiome Inc, this study was recently published in Nature Communications.

Kong J, Ha D, Lee J, Kim I, Park M, Im SH, Shin K, Kim S.
Network-based machine learning approach to predict immunotherapy response in cancer patients.
Nat Commun. 2022 Jun 28;13(1):3703. doi: 10.1038/s41467-022-31535-6

Most Popular Now

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...